Despite this, flutamide was not as active an initial agent as DES.

Will either of these agents offer clinical benefits beyond those offered by flutamide?

DHT-mediated development was more sensitive to in utero flutamide exposure than T-dependent processes.

Twenty-eight patients receiving flutamide have reached twelve weeks, while 8 have reached twenty-four weeks.

Side effects were minimal, and flutamide was well tolerated.

Prenatal flutamide exposure resulted in dose-responsive increases in cryptorchidism.

The effect of flutamide on cortisol metabolism was studied in eight patients with prostate cancer.

No serious toxicity attributable to flutamide was observed.

This case reminds us that patients who are receiving flutamide should be regularly monitored for liver function.

However, flutamide given in a similar treatment schedule did increase the TDI in GnRH-ant plus testosterone-treated rats.

Finally, flutamide was observed to be a weak partial agonist of the wild-type AR in this system.

If drug-induced liver injury is suspected, flutamide must be discontinued promptly to avoid progression of liver injury.

Gastrointestinal toxicity was the reason for trial discontinuation in seven patients receiving flutamide and two patients receiving prednisone.

These data suggest that androgen deprivation therapy with flutamide may be an effective and safe treatment for BPH.

The low incidence of DBP-induced intraabdominal testes contrasted with the high incidence of inguinal testes seen with flutamide.

It was concluded that flutamide may be a safe and effective drug for the treatment of symptomatic BPH.